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Rapamycin analogs that inhibit mTOR signaling have antitumor activity against certain lymphomas, but treatment of solid 
tumors has been less encouraging despite inhibition of mTOR function. Two recent papers give insight into the potential use 
of mTOR inhibitors. O’Reilly et al. provide evidence that poor tumor response to rapamycins is the result of relieving mTOR-
mediated feedback inhibition of insulin receptor substrate 1, and activation of Akt-mediated survival. In the second paper, 
Kaper et al. address the impact of pathway activation on hypoxia-mediated downregulation of mTOR signaling, raising the 
possibility that rapalogs could selectively inhibit hypoxic cells.Signaling pathways upstream of mTOR 
are dysregulated in multiple human can-
cers, which might make them susceptible 
to mTOR inhibition (so-called “oncogene 
addiction”). For example, recent data 
from genomic sequencing of tumor sam-
ples identified mutations in PIK3CA, the 
gene encoding the p110α subunit of 
phosphatidylinositol 3′ kinase (PI3K) in 
approximately 30% of colon and breast 
cancers. Although not all of the mutations 
have been shown to activate PI3K, there 
is supporting evidence that this might be 
the case, since the PIK3CA and PTEN 
mutations within the analyzed samples 
were mutually exclusive. This is consist-
ent with the idea that both events lead to 
an increase in the second messenger 3′ 
phosphorylated inositol membrane lipids 
required to activate the kinase signaling 
cascade. PTEN deletions, or inactivating 
mutations, are frequently present in car-
cinomas of the breast and prostate and 
also gliomas.
The insulin-like growth factors (IGF-
I/II) are also implicated in numerous can-
cers. The IGF/insulin pathway is unique 
in that, upon ligand binding and receptor 
autophosphorylation, insulin receptor 
substrate 1 (IRS-1) associates with these 
receptors. Tyrosine phosphorylation of 
IRS-1 in turn leads to the binding and 
activation of PI3K. The phosphorylation 
of inositol membrane lipids at the 3′ posi-cancer cell march 2006 tion by PI3K is a critical step in the IGF-IR 
signaling pathway. A number of kinases 
have been identified that associate with 
these 3′ phosphorylated membrane lip-
ids and subsequently participate in the 
kinase signaling cascade. Akt, one of the 
kinases in this activation cascade, has a 
distinct function in promoting cell survival 
by phosphorylating and blocking the proa-
poptotic activity of proteins such as BAD, 
FoxO transcription factors, and GSK-3α/β 
(reviewed in Plas and Thompson, 2005) 
(Figure 1). Akt also positively controls 
cell proliferation via phosphorylation and 
inactivation of TSC2, thereby blocking the 
inhibitory effects of the tuberous sclerosis 
complex (TSC) on the rapamycin-sensi-
tive mTOR complex (mTORC1) (Inoki 
et al., 2002; Potter et al., 2002; Dan et 
al., 2002). The TSC complex, along with 
Rheb which is considered an activator of 
mTOR, facilitates mTORC1 sensing of 
the cellular environment. The activity of 
mTORC1 is negatively regulated by amino 
acid deprivation, elevated AMP, or low O2 
(Bjornsti and Houghton, 2004). Activated 
mTORC1 (comprised of mTOR, Raptor, 
and GβL/mLST8) phosphorylates 4EBP1 
and S6K1. Phosphorylation of 4EBP1 
results in its release from the translation 
initiation factor eIF4E, and the assembly 
of the preinitiation translation complex 
eIF4G (Pause et al., 1994). Activation 
of mTORC1 also leads to phosphoryla-tion of S6K1, which is required for its full 
activation by PDK1, and assembly of the 
preinitiation complex required for efficient 
translation of RNAs with secondary 5′ 
structures (Holz et al., 2005). Importantly, 
activation of S6K1 represses upstream 
signaling through phosphorylation of IRS-
1 and its subsequent proteasome-medi-
ated degradation (Haruta et al., 2000).
Rationale for combining inhibitors in 
the mTOR pathway
Rapamycin, a macrocylic antibiotic in com-
plex with a 12 kDa immunophillin (FKBP12) 
potently inhibits mTORC1 signaling, result-
ing in cytostatic or cytotoxic effects on can-
cer cells. Consistent with the “oncogene 
addiction” hypothesis, several studies have 
indicated that cells lacking PTEN function, 
and hence constitutive Akt activation, are 
hypersensitive to rapamycin (reviewed 
in Hay, 2005). However, there are clear 
exceptions, and reexpression of PTEN 
does not necessarily induce resistance to 
rapamycin. Other factors clearly modulate 
sensitivity to rapamycins. IGF-I and, less 
potently, insulin are unique among growth 
factors tested in their ability to overcome 
the inhibitory effects of rapamycin on pro-
liferation and apoptosis (Hosoi et al., 1999). 
However, for most cancer cells under nor-
mal growth conditions with exogenous 
growth factors, the effect of rapamycin and 
its analogs is largely cytostatic, leading to 
decreased transit through G1 phase and 153
	 p r e v i e w sFigure 1. Self-regulation of the IGF-I signaling pathway
Ligand binding induces IGF-Ir phosphorylation and association of IrS-1, which in turn is phos-
phorylated on multiple sites, resulting in the recruitment of the p110 catalytic subunit of PI3K. 
akt phosphorylates and inhibits the function of TSc2, thus relieving the negative constraints on 
rheb, leading to mTOr activation. Phosphorylation of S6K1 by mTOr leads to phosphorylation 
of IrS-1 and its degradation via the proteasome (broken red arrow). a second feedback loop 
that senses inhibition of translation activates mTOr, leading to phosphorylation of ribosomal 
protein S6 (broken red arrow).accumulation of cells in G1. The anecdotal 
finding that inhibition of mTOR increased 
phosphorylation and activation of Akt in 
many cell lines thus raised the possibil-
ity that this feedback loop in which S6K1 
phosphorylated and downregulated IRS-1 
may serve to protect cells from rapamy-
cin-induced inhibition of proliferation and 
potentially apoptosis (Shi et al., 2005). The 
study from Rosen’s laboratory elegantly 
demonstrates this. Using cancer cells either 
wild-type or mutant for PTEN, it was shown 
that rapamycin induced rapid and sus-
tained increases in p-Akt (Ser473) and its 
downstream substrates (FoxO transcription 
factors and GSK3α/β). Importantly, similar 
increases in p-Akt in cancer biopsies from 
patients treated for 4 weeks with the rapa-
log RAD001 were also found. Increased 
p-Akt was correlated with increased levels 
of IRS-1 but not IRS-2. To test the idea 
that increased p-Akt was a consequence 
of decreased feedback on the IGF-I sig-
naling pathway, O’Reilly et al. (2006) 
used a small molecule inhibitor of IGF-IR, 
NVP-AE541, and an antibody specifically 154 directed against the IGF-IR. Pretreatment 
with either receptor inhibitor abrogated 
rapamycin-induced p-Akt induction and 
substrate phosphorylation. Combination 
of rapamycin with NVP-AE541 had addi-
tive effects on proliferation irrespective of 
PTEN status and increased apoptosis in a 
PTEN mutant cancer cell line. Thus, these 
results indicate a clear strategy for com-
bining an mTOR inhibitor with an IGF-IR 
inhibitor or possibly an inhibitor of PI3K, 
although this latter strategy may be associ-
ated with unacceptable hyperglycemia.
The report by Kaper et al. (2006) 
also addresses activation upstream of 
mTOR and cellular responses to hypoxia. 
Inhibition of mTOR by hypoxia (usually 
1% O2) requires the TSC complex and the 
hypoxia-inducible gene REDD1/RTP801, 
the product of which may act upstream of 
the TSC (Brugarolas et al., 2004). Using 
U251 cells engineered to inducibly express 
PTEN, wild-type MEFs, or TSC2−/− MEFs, 
it was shown that activation of the pathway 
upstream prolonged mTORC1 signaling 
under hypoxia. Consistent with activation of the mTORC1 pathway, protein synthesis 
was increased under normoxic conditions, 
and PTEN null or TSC2 null cells main-
tained protein synthesis for longer periods 
under hypoxia. Mutations activating mTOR 
signaling, or overexpression of mTOR 
itself, did not maintain DNA synthesis 
under hypoxia but did result in enhanced 
transcription and translation of hypoxia-
inducible genes. Interestingly, while TSC 
null cells were somewhat resistant to 
hypoxia-induced apoptosis, rapamycin did 
not reverse this effect, implicating a TSC-
dependent, mTOR-independent survival 
pathway. Notably, the effect of hypoxia in 
suppressing downstream phosphorylation 
of mTOR substrates (4E-BP1 and S6K1) 
was less pronounced than that of rapamy-
cin treatment, suggesting that repression of 
mTOR activity by lowered O2 is not as effi-
cient as repression by rapamycin. However, 
this neglects an observation made over 30 
years ago that inhibition of translation itself 
leads to enhanced phosphorylation of S6. 
For example, translation inhibitors such 
as anisomycin or cycloheximide induce 
activation of mTOR and rapamycin-sensi-
tive phosphorylation of its substrates (see 
Brown and Schreiber, 1996). Considering 
that nutritional deprivation (e.g., amino 
acid restriction) and hypoxia both reduce 
mTOR signaling, is it likely that mTOR real-
ly functions in hypoxic areas of tumors? To 
address this issue, xenograft tumors were 
developed from wild-type or TSC−/− MEFs. 
TSC−/− tumors established more rapidly 
than wild-type, suggesting that enhanced 
mTOR signaling and translation and 
expression of hypoxia-induced genes is 
advantageous only in early establishment 
of tumors. Importantly, using a pentafluori-
nated derivative of etanidazole that forms 
adducts with cellular macromolecules 
under hypoxic conditions, and immunos-
taining for phospho-4E-BP1, it was shown 
that hyperphosphorylated 4E-BP1-positive 
cells were observed occasionally in hypox-
ic regions of tumors. Whether this feedback 
to activate mTOR increases cell survival in 
hypoxia has not been elucidated. However, 
it is clear that autoregulatory loops exist to 
regulate input proximal to mTOR (i.e., feed-
back inhibition of IRS-1 through S6K1) and 
distal to mTOR via sensors of translation 
(Khaleghpour et al., 1999).
Conclusion
The O’Reilly paper demonstrates that 
effective strategies to target cancer cells 
require a greater understanding of the 
effects of disrupting the homeostatic 
mechanisms of growth control if these 
pathways are going to be successfully tar-cancer cell march 2006
	 p r e v i e w sgeted in the treatment of cancer. The work 
by Kaper et al. focuses our attention on 
activation of the PI3K pathway upstream 
of mTOR and the potential role of mTOR 
inhibitors in selective inhibition of hypoxic 
cells. A common theme that emerges 
from these and other recent reports is 
that signaling pathways are neither lin-
ear nor unidirectional, being regulated by 
compensatory feedback mechanisms to 
allow cells to survive. This is nicely dem-
onstrated when distinct steps in the PI3K 
pathway are inhibited.
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